Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytosorbents

1.10
+0.01000.92%
Post-market: 1.100.00000.00%16:00 EDT
Volume:51.85K
Turnover:56.01K
Market Cap:68.75M
PE:-2.89
High:1.12
Open:1.12
Low:1.05
Close:1.09
Loading ...

CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

PR Newswire
·
21 Apr

BRIEF-Cytosorbents Appoints Thomas Shannon As Vice President Of Marketing For North America

Reuters
·
14 Apr

Press Release: CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

Dow Jones
·
14 Apr

BRIEF-Cytosorbents Corp - Extends Expiration Date Of Series B Right Warrants To June 10, 2025 - SEC Filing

Reuters
·
04 Apr

Cytosorbents Corp - Extends Expiration Date of Series B Right Warrants to June 10, 2025 - SEC Filing

THOMSON REUTERS
·
04 Apr

CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants

PR Newswire
·
04 Apr

CTSO: CytoSorbents Reports 4th quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations.

Zacks Small Cap Research
·
04 Apr

Cytosorbents Price Target Maintained With a $1.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

Cytosorbents’ Neutral Rating Amid Revenue Shortfall and Strategic Reorganization

TIPRANKS
·
03 Apr

Cytosorbents Is Maintained at Buy by D. Boral Capital

Dow Jones
·
01 Apr

CytoSorbents Corp (CTSO) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com
·
01 Apr

BRIEF-Cytosorbents Reports Fourth Quarter And Full Year 2024 Financial Results And Recent Business Highlights

Reuters
·
01 Apr

BRIEF-Cytosorbents Corp - On March 25, Determined To Restate 2023 Financial Statements Due To Misstatements - SEC Filing

Reuters
·
01 Apr

Cytosorbents Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Apr

Cytosorbents Corp - on March 25, Determined to Restate 2023 Financial Statements Due to Misstatements - SEC Filing

THOMSON REUTERS
·
01 Apr

CytoSorbents Q4 2024 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $9.200M Miss $10.100M Estimate

Benzinga
·
01 Apr

CytoSorbents reports Q4 adjusted EPS (3c) vs. (17c) last year

TIPRANKS
·
01 Apr

Cytosorbents FY Product Gross Margin 71%

THOMSON REUTERS
·
01 Apr

Cytosorbents FY EPS USD -0.38

THOMSON REUTERS
·
01 Apr

Cytosorbents Corp: Expect Modest Decline in Overall Product Sales for Q1 2025

THOMSON REUTERS
·
01 Apr